Le Lézard42m
Signal12 Achieves FDA Alignment, Accelerating Pro-oculartm Towards Phase 3 Clinical Trials for Ocular Graft-versus-Host Disease
Signal12, Inc. (Signal12), a clinical-stage ophthalmic pharmaceutical company focused on first-of-a-kind patented technologies that enable existing drugs to act through unique neural pathways, today ...
Signal12 Achieves FDA Alignment, Accelerating Pro-ocular™ Towards Phase 3 Clinical Trials for Ocular Graft-versus-Host Disease
Signal12, Inc. (Signal12), a clinical-stage ophthalmic pharmaceutical company focused on first-of-a-kind patented technologies that enable existing drugs to act through unique neural pathways, today ...
Orca Bio makes a splash as T-cell therapy cuts GvHD in blood cancer patients
Graft versus host disease (GvHD) is a complication from stem cell transplants where the patient recognises the cells as foreign and rejects them.
BioPharma Dive21h
Orca Bio to seek approval of T cell transplant after positive trial data
Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...